[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368719-105":59,"doc-detail-368719-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","landscape-analysis-of-cldn18-expression-and-isoform-distribution-in-solid-tumors-insights-from-monstar-screen-2-study","Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors - Insights From MONSTAR-SCREEN-2 Study","","Claudin 18.2 (CLDN18.2) is presented as an emerging therapeutic target in oncology, yet pan-cancer expression patterns and isoform distributions remain insufficiently described. This study analyzes CLDN18 expression across solid tumors enrolled in MONSTAR-SCREEN-2 using immunohistochemistry (n=349) and whole-transcriptome sequencing (n=2191). Splice-junction analysis characterizes isoform distributions and assesses treatment-related temporal changes. Results show IHC positivity (≥40% stained tumor cells) in 16.3% overall, highest in gastric, biliary tract, pancreatic, and small intestinal cancers, with strong WTS-IHC correlation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/landscape-analysis-of-cldn18-expression-and-isoform-distribution-in-solid-tumors-insights-from-monstar-screen-2-study/368719/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/landscape-analysis-of-cldn18-expression-and-isoform-distribution-in-solid-tumors-insights-from-monstar-screen-2-study/368719.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapeutic target does the study focus on?","Question",{"text":113,"@type":114},"The study focuses on Claudin 18.2 (CLDN18.2), an isoform of the tight junction protein Claudin 18 (CLDN18).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were CLDN18 expression and isoform distributions measured?",{"text":118,"@type":114},"CLDN18 expression was evaluated using immunohistochemistry (IHC) and whole-transcriptome sequencing (WTS). Splice-junction analysis was used to characterize isoform distribution patterns in WTS data.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key findings about CLDN18.2 prevalence across cancers?",{"text":122,"@type":114},"IHC detected CLDN18.2 positivity (≥40% tumor cells with any staining intensity) in 16.3% of patients, with the highest prevalence in gastric, biliary tract, pancreatic, and small intestinal cancers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368719,1790358529,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nLandscape Analysis ofCLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study  \nTadayoshi Hashimoto1,2  | Naoko Iida1 | Yoshiaki Nakamura1,2  | Norio Nonomura3  | Chigusa Morizane4 |  \nHiroji Iwata5  | Susumu Okano6  | Wataru Yamagami7 | Naoya Yamazaki8  | Shigenori Kadowaki9 | Makoto Ueno10 | Shogen Boku11  | Eiji Oki12  | Yoshito Komatsu13 | Satoshi Yuki14  | Akitaka Makiyama15,16 |  \nTakatsugu Ogata17 | Naoki Takahashi18 | Naohiro Okano19  | Tomohiro Nishina20 | Naoya Sakamoto21  | Takeshi Kuwata22 | Riu Yamashita23 | Taro Shibuki1 | Mitsuho Imai1 | Takao Fujisawa1,6 | Hideaki Bando1,2  | Kohei Shitara2  | Takayuki Yoshino2   \n1Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan | 2Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan | 3Department of Urology, Osaka University Graduate School of Medicine, Suita,  \nJapan | 4Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan | 5Department of Advanced Clinical Research and Development, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan | 6Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan | 7Department of Obstetrics & Gynecology, Keio University School of Medicine, Tokyo, Japan | 8Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan | 9Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan | 10Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan | 11Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan | 12Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan | 13Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan | 14Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan | 15Cancer Center, Gifu University Hospital, Gifu, Japan | 16Center for One Medicine Innovative Translational Research, Gifu University, Gifu, Japan | 17Department of Medical Oncology, Osaka International Cancer Institute Osaka Prefectural Hospital Organization, Osaka, Japan | 18Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan | 19Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan | 20Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan | 21Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan | 22Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan | 23Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan  \nCorrespondence: Yoshiaki Nakamura ([yoshinak@east.ncc.go.jp](yoshinak@east.ncc.go.jp))  \nReceived: 21 February 2025 | Revised: 5 April 2025 | Accepted: 6 May 2025  \nFunding: This work was supported by the Japan Agency for Medical Research and Development (24ck0106890h0002) and SCRUM-Japan Funds  \n([http://www.scrum-japan.ncc.go.jp/index.html](http://www.scrum-japan.ncc.go.jp/index.html)).  \nKeywords: claudin18 | immunohistochemistry | isoform | pan-cancer | whole-transcriptome sequencing  \n\n| ABSTRACT\u003Cbr>Claudin 18.2 (CLDN18.2), a tight junction protein isoform, is an emerging therapeutic target in oncology. CLDN18 is wellcharacterized in gastric cancer, but its pan-cancer expression profiles and isoform distributions are poorly documented. In the |\n| --- |\n|  |\n| Abbreviations: ADC, Antibody–drug conjugate; BRCA, Breast cancer; BTC, Biliary tract cancer; CAR-T, Chimeric antigen receptor T; CERVC, Cervical cancer; CLDN18, Claudin 18; CRC, Colorectal cancer; ENDC, endometrial cancer; ESOC, Esophageal cancer; GC, Gastric cancer; GIST, Gast","cbCaiqSBCfdnsULn","https://ap.wps.com/l/cbCaiqSBCfdnsULn","pdf",4355409,14,"English","# Introduction\n## Methods (MONSTAR-SCREEN-2)\n## Results (IHC and WTS findings)\n## Correlation and Conclusion","[{\"question\":\"What therapeutic target does the study focus on?\",\"answer\":\"The study focuses on Claudin 18.2 (CLDN18.2), an isoform of the tight junction protein Claudin 18 (CLDN18).\"},{\"question\":\"How were CLDN18 expression and isoform distributions measured?\",\"answer\":\"CLDN18 expression was evaluated using immunohistochemistry (IHC) and whole-transcriptome sequencing (WTS). Splice-junction analysis was used to characterize isoform distribution patterns in WTS data.\"},{\"question\":\"What were the key findings about CLDN18.2 prevalence across cancers?\",\"answer\":\"IHC detected CLDN18.2 positivity (≥40% tumor cells with any staining intensity) in 16.3% of patients, with the highest prevalence in gastric, biliary tract, pancreatic, and small intestinal cancers.\"}]","Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors - Insights From MONSTAR-SCREEN-2 Study | PDF",1790178174,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7930a3a176303a262e2d572f63606521.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a642c7afcb090c95f548bda7917c2b03.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2efca968f09a9126b5fc4fb752af1cbc.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5f160d6d70111419ce679dc72d6f8e7.webp",980,1287]